Olema Pharmaceuticals (OLMA) Stock Price, News & Analysis

Company Overview

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Key Stats

• Today's Range: $7.91 to $8.90
• 50-Day Range: $7.87 to $13.64
• 52-Week Range: $7.68 to $16.77
• Volume: 1.21 million shs
• Average Volume: 489,837 shs
• Market Capitalization: $503.09 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $27.00
• Consensus Rating: Buy

Olema Pharmaceuticals Stock Analysis - MarketRank™

Olema Pharmaceuticals scored higher than 41% of companies evaluated by MarketBeat, and ranked 725th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Olema Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Olema Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Olema Pharmaceuticals are expected to decrease in the coming year, from ($2.36) to ($2.60) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Olema Pharmaceuticals is -4.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Olema Pharmaceuticals is -4.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Olema Pharmaceuticals has a P/B Ratio of 2.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.50% of the outstanding shares of Olema Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Olema Pharmaceuticals has a short interest ratio ("days to cover") of 17.9, which indicates bearish sentiment.

Change versus previous month

Short interest in Olema Pharmaceuticals has recently decreased by 2.24%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Olema Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Olema Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

14.50% of the outstanding shares of Olema Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Olema Pharmaceuticals has a short interest ratio ("days to cover") of 17.9, which indicates bearish sentiment.

Change versus previous month

Short interest in Olema Pharmaceuticals has recently decreased by 2.24%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.54

News Sentiment

Olema Pharmaceuticals has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Olema Pharmaceuticals this week, compared to 3 articles on an average week.

Search Interest

4 people have searched for OLMA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Olema Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Olema Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.40% of the stock of Olema Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

91.78% of the stock of Olema Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

OLMA Stock Analysis - Frequently Asked Questions

How have OLMA shares performed this year?

Olema Pharmaceuticals' stock was trading at $14.03 at the beginning of the year. Since then, OLMA shares have decreased by 37.4% and is now trading at $8.78.
View the best growth stocks for 2024 here.

How were Olema Pharmaceuticals' earnings last quarter?

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) posted its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.54) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.54).

When did Olema Pharmaceuticals IPO?

Olema Pharmaceuticals (OLMA) raised $170 million in an initial public offering on Thursday, November 19th 2020. The company issued 10,000,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies, Cowen and Canaccord Genuity served as the underwriters for the IPO.

Who are Olema Pharmaceuticals' major shareholders?

Top institutional shareholders of Olema Pharmaceuticals include Point72 Asset Management L.P. (6.44%), State Street Corp (3.44%), Wellington Management Group LLP (1.75%) and Great Point Partners LLC (1.75%). Insiders that own company stock include Bvf Partners L P/Il, G Walmsley Graham, Biocapital Advisors L Paradigm, Cyrus Harmon, David C Myles, Sean Bohen, Naseem Zojwalla and Kinney Horn.
View institutional ownership trends.

How do I buy shares of Olema Pharmaceuticals?

Shares of OLMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Olema Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Olema Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and Jabil (JBL).

Company Calendar

• Last Earnings: 8/06/2024
• Today: 11/23/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/10/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:OLMA
• CUSIP: N/A
• CIK: 1750284
• Web: www.olema.com
• Phone: 650-243-5555
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $27.00
• High Stock Price Target: $31.00
• Low Stock Price Target: $20.00
• Potential Upside/Downside: +207.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.19)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-96,650,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -53.56%
• Return on Assets: -47.86%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.10
• Quick Ratio: 7.10

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.47 per share
• Price / Book: 2.53

Miscellaneous

• Outstanding Shares: 57,300,000
• Free Float: 46,182,000
• Market Cap: $503.09 million
• Optionable: Optionable
• Beta: 2.02